Is AIDX diluting shareholders?

Read three numbers together: shares outstanding over time (10.6M as of 2026-05-19), warrants that can convert into new shares (2,169 reported), and how much cash runway remains (~26.373214843831395 months). A company short on cash with live registrations is structurally likely to issue shares.

Where do these numbers come from?

SEC EDGAR only: the XBRL company-facts API for shares, warrants and cash, and filing metadata for registrations and pricings. Every figure shows its source form, and nothing here is estimated by us beyond the arithmetic stated next to it.

Why might a warrant tranche be missing from the table?

The tranche table is built from the dimensions the company tagged in its own 10-Q or 10-K XBRL. A tranche the filer chose not to dimension does not appear, and its absence proves nothing: the exhibits remain the ground truth. Everything shown carries the filing it came from.

Dilution profile // every instrument, one screen, from SEC filings

20/20 Biolabs, Inc. (AIDX)

CIK 1139685 · all EDGAR filings →

Overall dilution risk

HIGHworst of 4 computed signals (offering ability)

= the worst band among the computed sub-ratings, no hidden weighting

Offering ability

HIGH$191M registered

= total registered offering amount from the fee exhibits of live registrations (bands: $1M / $20M)

registered capacity, not remaining: amounts already taken down are not subtracted yet

Overhead supply

LOWwarrants = 0% of O/S

= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)

warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this

Historical dilution

LOW+2% O/S in 3y

= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative

Cash need

LOW~26.4 months of runway

= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

Latest: 10.6M shares as of May 19, 2026 (10-Q).

Cash runway

Self-funding

generates cash

Full breakdown: cash runway tool · source filing →

Warrants

Tranche	Warrants	Exercise price	Term	Notes
Warrant	3.5M	$11.42	—	FV $5.0M
Placement Agent Warrants	2,022	not tagged	5y	—

Tranches exactly as the company dimensioned them in its 10-Q filed May 20, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

Warrants outstanding: 2,169 underlying shares, as reported Dec 31, 2025 (10-K).

Rough fully diluted estimate: 10.6M = 10.6M O/S + 2,169 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

Note	Principal	Carrying	Conv. price	Rate	If converted
Convertible Promissory Notes Prior Equity Crowdfunding	$306,716	—	not tagged	—	—

Notes exactly as the company dimensioned them in its 10-Q filed May 20, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding	10.6M	May 19, 2026
+ Warrant (if exercised)	3.5M	Feb 19, 2026
+ Placement Agent Warrants (if exercised)	2,022	Feb 9, 2026
Fully diluted estimate	14.1M	+33.0% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

Registered offering capacity on live registrations: $191.1Mfrom the structured fee exhibits; registered is not remaining, takedowns are not subtracted

S-1Apr 6, 2026$18.3M registeredfiling →

S-1Dec 12, 2025$172.8M registeredfiling →

Last 12 months: 0 executed · 4 registered.

UPDATEMay 21, 2026Prospectus update — often a resale registration, not necessarily new capital424B3 →

UPDATEApr 28, 2026Prospectus update — often a resale registration, not necessarily new capital424B3 →

UPDATEApr 13, 2026Prospectus update — often a resale registration, not necessarily new capital424B3 →

EFFECTIVEApr 10, 2026SEC declared a registration effective — selling can beginEFFECT →

EFFECTIVEApr 9, 2026SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDApr 6, 2026S-1 registration — capacity to sell shares, not a sale yetS-1 →

UPDATEFeb 18, 2026Prospectus update — often a resale registration, not necessarily new capital424B3 →

EFFECTIVEFeb 17, 2026SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDJan 26, 2026S-1/A registration — capacity to sell shares, not a sale yetS-1/A →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full AIDX workspace